A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma

Journal of Medicinal Chemistry

Volumn 47, Issue 20, 2004, Pages 4950-4957

  Hersperger, Rene ^a   Buchheit, Karl Heinz ^a,b   Cammisuli, Salvatore ^a   Enz, Albert ^a   Lohse, Olivier ^a   Ponelle, Monique ^a   Schuler, Walter ^a   Schweitzer, Alain ^a   Walker, Christoph ^a   Zehender, Hartmut ^a   Zenke, Gerhard ^a   Zimmerlin, Alfred G ^a   Zollinger, Markus ^a   Mazzoni, Lazzaro ^a   Fozard, John R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b European Network of National Information Centers   (France)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYL 1,14 DIHYDROXY 12 [2 [3 METHOXY 4 (4 METHOXYCARBONYLMETHYLPHENYLENE CARBAMOYLOXY)CYCLOHEXYL] 1 METHYLVINYL] 23,25 DIMETHOXY 13,19,21,27 TETRAMETHYL 11,28 DIOXA 4 AZATRICYCLO[22.3.1.0 4,9 ]OCTACOS 18 ENE 2,3,10,16 TETRAONE; [4 [4 [2 (17 ALLYL 1,14 DIHYDROXY 23,25 DIMETHOXY 13,19,21,27 TETRAMETHYL 2,3,10,16 TETRAOXO 11,28 DIOXA 4 AZATRICYCLO[22.3.1.0 4,9 ]OCTACOS 18 EN 17 YL)PROPENYL] 2 METHOXYCYCLOHEXYLOXYCARBONYLAMINO]PHENYL]ACETIC ACID; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; MLD 987; TACROLIMUS; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; IC 50; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; RAT; RHESUS MONKEY; T LYMPHOCYTE ACTIVATION; TH2 CELL;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; AREA UNDER CURVE; ASTHMA; BIOCHEMISTRY; CELLS, CULTURED; DRUG DESIGN; EOSINOPHILS; HALF-LIFE; HUMANS; MACACA MULATTA; MACROLIDES; RATS; RATS, INBRED BN; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; TACROLIMUS;

EID: 4544269656     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031101l     Document Type: Article

References (36)

1. Bousquet, J.; Jeffery, P. K.; Busse, W. W.; Johnson, M.; Vignola, A. M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 2000, 161 (5), 1720-1745.
2. Corrigan, C. J.; Kay, A. B. CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status. Am. Rev. Respir. Dis. 1990, 141, 970-977.
3. Robinson, D. S.; Hamid, Q.; Ying, S.; Tsicopoulos, A.; Barkans, J.; Bentley, A. M.; Corrigan, C.; Durham, S. R.; Kay, A. B. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 1992, 326 (5), 298-304.
4. Walker, C.; Virchow, J. C.; Bruijnzeel, P. L.; Blaser, K. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J. Immunol. 1991, 146 (6), 1829-1835.
5. Anderson, G. P.; Coyle, A. J. TH2 and TH2-like cells in allergy and asthma: Pharmacological perspectives. Trends Pharmacol. Sci. 1994, 15 (9), 324-332.
6. Glucocorticosteroids. In The Pharmacology of Lymphocytes, Handbook of Experimental Pharmacology; Behrens, T. W., Goodwin, J. S., Bray, M. A., Morley, J., Eds.; Springer-Verlag: New York, 1988; pp 428-439.
7. Alexander, A. G.; Barnes, N. C.; Kay, A. B. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992, 339 (8789), 324-328.
8. Lock, S. H.; Kay, A. B.; Barnes, N. C. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid- dependent asthma. Am. J. Respir. Crit. Care Med. 1996, 153 (2), 509-514.
9. Sihra, B. S.; Kon, O. M.; Durham, S. R.; Walker, S.; Barnes, N. C.; Kay, A. B. Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax 1997, 52 (5), 447-452.
10. Barnes, P. J.; Pedersen, S.; Busse, W. W. Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med. 1998, 157 (3, Pt. 2), S1-S53.
11. Leung, D. Y.; Szefler, S. J. New insights into steroid resistant asthma. Pediatr. Allergy Immunol. 1998, 9 (1), 3-12.
12. Haczku, A.; Alexander, A.; Brown, P.; Assoufi, B.; Li, B.; Kay, A. B.; Corrigan, C. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: Comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. J. Allergy Clin. Immunol. 1994, 93 (2), 510-509.
13. Arai, T.; Koyama, Y.; Suenaga, T.; Honda, H. Ascomycin, an antifungal antibiotic. J. Antibiot. 1962, 15 (Ser. A), 231-232.
14. Kino, T.; Hatanaka, H.; Hashimoto, M.; Nishiyama, M.; Goto, T.; Okuhara, M.; Kihsaka, M.; Aoki, H.; Imanaka, H. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. J. Antibiot. 1987, 40, 1249-1255.
15. Ho, S.; Clipstone, N.; Timmermann, L.; Northrop, J.; Graef, I.; Fiorentino, D.; Nourse, J.; Crabtree, G. R. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 1996, 80 (3, Pt. 2), S40-S45.
16. Henry, M. L. Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles. Clin. Transplant. 1999, 13 (3), 209-220.
17. Hersperger, R.; Schuler, W.; Zenke, G. Preparation and immunosuppressive activity of 32-(O)-acylated and 32-(O)-thioacylated analogues of ascomycin. Bioorg. Med. Chem. Lett. 1999, 9 (2), 227-232.
18. Rohatagi, S.; Calic, F.; Harding, N.; Ozoux, M. L.; Bouriot, J. P.; Kirkesseli, S.; DeLeij, L.; Jensen, B. K. Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. J. Clin. Pharmacol. 2000, 40 (11), 1211-1226.
19. Underwood, S. L.; McMillan, S.; Reeves, R.; Hunt, J.; Brealey, C. J.; Webber, S.; Foster, M.; Sargent, C. A. Effects of cyclosporin A administered into the airways against antigen-induced airway inflammation and hyperreactivity in the rat. Eur. J. Pharmacol. 2001. 420 (2, 3), 165-173.
20. Lazarova, T.; Chen, J. S.; Hamann, B.; Kang, J. M.; Homuth-Trombino, D.; Han, F.; Hoffmann, E.; McClure, C.; Eckstein, J.; Or, Y. S. Synthesis and biological evaluation of novel cyclosporin A analogues: Potential soft drugs for the treatment of autoimmune diseases. J. Med. Chem. 2003, 46 (5), 674-676.
21. Hersperger, R.; Keller, T. H. Ascomycin derivatives and their use as immuosuppressive agents. Drugs Future 2000, 25 (3), 269-277.
22. Bodor, N.; Buchwald, P. Soft drug design: General principles and recent applications. Med. Res. Rev. 2000, 20 (1), 58-101.
23. Edmunds, A. J. F.; Baumann, K.; Grassberger, M.; Schulz, G. Highly selective reactions of FK506 with diazomethane. Tetrahedron Lett. 1991, 32 (48), 7039-7042.
24. Brands, K. M. J.; Dolling, U. H.; Jobson, R. B.; Marchesini, G.; Reamer, R. A.; Williams, J. M. Mild aryl ether formation in the semisynthesis of the novel macrolide immunosuppressant L-732,531. J. Org. Chem. 1998, 63 (3, 19), 6721-6726.
25. Mormann, W.; Leukel, G. A simple and versatile synthesis of trimethylsiloxy-substituted isocyanates. Synthesis 1988, 12, 990-992.
26. Plesner, A. Increasing the yield of human mononuclear cells and low serum conditions for in vitro generation of macrophages with M-CSF. J. Immunol. Methods 2003, 279 (1, 2), 287-295.
27. Kirby, J. G.; Hargreave, F. E.; Gleich, G. J.; O'Byrne, P. M. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am. Rev. Respir. Dis. 1987, 136 (2), 379-383.
28. Schneider, T.; van Velzen, D.; Moqbel, R.; Issekutz, A. C. Kinetics and quantitation of eosinophil and neutrophil recruitment to allergic lung inflammation in a brown Norway rat model. Am. J. Respir. Cell. Mol. Biol. 1997, 17 (6), 702-712.
29. Derendorf, H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir. Med. 1997, 91 (Suppl. A), 22-28.
30. Baumann, G.; Andersen, E.; Quesniaux, V.; Eberle, M. K. Cyclosporine and its analogue SDZ IMM 125 mediate very similar effects on T-cell activation-a comparative analysis in vitro. Transplant Proc. 1992, 24 (4, Suppl. 2), 43-48.
31. Sanglier, J. J.; Quesniaux, V.; Fehr, T.; Hofmann, H.; Mahnke, M.; Memmert, K.; Schuler, W.; Zenke, G.; Gschwind, L.; Maurer, C.; Schilling, W. Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp A92-308110-I. Taxonomy, fermentation, isolation and biological activity. J. Antibiot. 1999, 52, 466-473.
32. Schuler, W.; Sedrani, R.; Cottens, S.; Haberlin, B.; Schulz, M.; Schuurman, H. J.; Zenke, G.; Zerwes, H. G.; Schreier, M. H. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997, 64 (1), 36-42.
33. Trifilieff, A.; Walker, C.; Keller, T.; Kottirsch, G.; Neumann, U. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br. J. Pharmacol. 2002, 135, 1655-1664.
34. Coligan, et al. Current Protocols in Immunology; John Willey & Sons: 1994; Vol. 2, Section 2, Unit 7.10.
35. Enz, A.; Shapiro, G.; Chappuis, A.; Dattler, A. Nonradioactive assay for protein phosphatase 2B (calcineurin) activity using a partial sequence of the subunit of cAMP-dependent protein kinase as substrate. Anal. Biochem. 1994, 216 (1), 147-153.
36. Hersperger, R.; Bray-French, K.; Mazzoni, L.; Mueller, T. Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: A novel class of potent and selective phosphodiesterase type 4D inhibitors. J. Med. Chem. 2000, 43 (4), 675-682.